Review
Gastroenterology & Hepatology
Saleh A. Alqahtani, Massimo G. Colombo
Summary: The prevalence and burden of hepatitis C virus (HCV) in children are poorly understood. Vertical transmission and injection drug use are the main modes of infection. Early diagnosis and treatment are crucial in preventing HCV-induced severe liver disease. Direct-acting antiviral drugs have shown to be as safe and effective in young HCV patients as in adults.
LIVER INTERNATIONAL
(2021)
Article
Oncology
Luckshi Rajendran, Woo Jin Choi, Hala Muaddi, Tommy Ivanics, Jordan J. Feld, Marco P. A. W. Claasen, Matthew Castelo, Gonzalo Sapisochin
Summary: This study suggests that viral hepatitis status is not associated with 30-day post-hepatectomy complications, major complications, or PHLF in patients with HCC.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Maria M. Zanone, Claudia Marinucci, Alessia Ciancio, Dario Cocito, Federica Zardo, Emanuela Spagone, Bruno Ferrero, Cristina Cerruti, Lorena Charrier, Franco Cavallo, Giorgio M. Saracco, Massimo Porta
Summary: This longitudinal study assessed the prevalence and outcome of neuropathy in chronic HCV patients before and after DAA treatment. Results showed improvement in neuropathy after DAA therapy, supporting the need for larger intervention studies.
LIVER INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Hideki Hagiwara, Yasuharu Imai, Naoki Hiramatsu, Shinji Tamura, Keiji Yamamoto, Masahide Oshita, Kazuyoshi Ohkawa, Taizo Hijioka, Hiroyuki Fukui, Toshifumi Ito, Yoshinori Doi, Yukinori Yamada, Takayuki Yakushijin, Yuichi Yoshida, Tomohide Tatsumi, Tetsuo Takehara
Summary: A prediction model incorporating baseline BMI, FIB-4 index, albumin level, and alpha-foetoprotein level was developed to predict HCC occurrence after DAA-mediated SVR. The model showed high sensitivity and negative predictive value at 2 and 3 years post-SVR, providing an efficient surveillance strategy for HCC occurrence.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Pharmacology & Pharmacy
Mario Enrico Canonico, Giuseppe Damiano Sanna, Roberta Siciliano, Fernando Scudiero, Giovanni Esposito, Guido Parodi
Summary: HCV infection increases cardiovascular and bleeding risks, requiring concomitant use of antithrombotic therapies. However, there may be drug-drug interactions between antithrombotic drugs and HCV antiviral drugs.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Biagio Pinchera, Nicola Schiano Moriello, Antonio Riccardo Buonomo, Emanuela Zappulo, Giulio Viceconte, Riccardo Villari, Ivan Gentile
Summary: The gut microbiota plays a crucial role in HCV-related liver disease. HCV infection alters the gut microbiota, leading to an inflammatory state which can progress the liver disease. Direct acting antivirals (DAAs) not only eliminate the virus but also impact the gut microbiota of HCV patients. Understanding the gut microbiota in HCV-related liver disease is important for exploring new therapeutic opportunities.
MICROBIAL PATHOGENESIS
(2023)
Article
Medicine, General & Internal
Ryosaku Shirahashi, Toshikuni Suda, Masaya Tamano
Summary: This study examined the effects of DAA treatment on serum zinc levels in patients with hepatitis C, finding that DAA treatment can improve hypozincemia in these patients by restoring the function of serum albumin.
Review
Public, Environmental & Occupational Health
Pilar Hernandez-Con, Debbie L. Wilson, Huilin Tang, Ikenna Unigwe, Munaza Riaz, Natalie Ourhaan, Xinyi Jiang, Hyun Jin Song, Amanda Joseph, Linda Henry, Robert Cook, Dushyantha Jayaweera, Haesuk Park
Summary: Despite the availability of effective antiviral therapies, there are still persistent gaps in the HCV care cascade, especially among traditionally marginalized populations. Public health interventions targeting identified priority areas may help improve these issues.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Chun-Ting Chen, Ming-Ying Lu, Meng-Hsuan Hsieh, Pei-Chien Tsai, Tsai-Yuan Hsieh, Ming-Lun Yeh, Ching- Huang, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Yu-Lueng Shih, Ming-Lung Yu
Summary: This study implemented an outreach strategy, universal mass screening, and immediate onsite treatment with a simplified pan-genotypic direct-acting antivirals (DAA) regimen in a prison in Taiwan. The results showed that this approach successfully achieved micro-elimination of hepatitis C virus (HCV) among prisoners.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Endocrinology & Metabolism
Chun-Han Cheng, Chia-Ying Chu, Huan-Lin Chen, I-Tsung Lin, Chia-Hsien Wu, Yuan-Kai Lee, Ming-Jong Bair
Summary: This study analyzed the factors associated with insulin resistance (IR) in chronic HCV-infected patients and evaluated the changes in glucose homeostasis after treatment with direct-acting antiviral agents (DAAs). The results showed that obesity, treatment experience, high serum ALT and triglyceride levels, as well as advanced hepatic fibrosis were independently associated with IR in these patients. After viral elimination with DAA therapy, there was a significant reduction in mean HOMA-IR in patients with baseline high IR, HCV genotype 1, and treatment experience.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Multidisciplinary Sciences
Daniel Melendez-Mena, Miguel Angel Mendoza-Torres, Virginia Sedeno-Monge, Victor Hugo Garcia y Garcia, Elain Rivera-Garcia, Laura Sanchez-Reza, Maria del Carmen Baxin Dominguez, Belinda Guzman-Flores, Ygnacio Martinez-Laguna, Jose Manuel Coronel Espinoza, Ivan Galindo-Santiago, Juan Carlos Flores-Alonso, Veronica Vallejo-Ruiz, Paulina Cortes-Hernandez, Julio Reyes-Leyva, Francisca Sosa-Jurado, Gerardo Santos-Lopez
Summary: The study reported excellent SVR rates with DAAs in Mexican patients who had not responded to PegIFNα2a+RBV therapy, with improvements in CPS, FIB-4, and APRI. DAA treatment led to a significant reduction in liver transaminases, suggesting a potential decrease in hepatic necroinflammation.
Article
Health Care Sciences & Services
Shashi N. Kapadia, Phyllis Johnson, Kristen M. Marks, Bruce R. Schackman, Yuhua Bao
Summary: The study found that HCV treatment providers are mainly gastroenterologists, but the treatment scale is gradually expanding. Patients receiving treatment from general medicine or nonphysician providers had a similar likelihood of treatment completion compared to those treated by gastroenterologists.
Article
Gastroenterology & Hepatology
Ahmed Fayed, Mohamed Tharwat Hegazy, Lucie Biard, Matheus Vieira, Tarek El Shabony, David Saadoun, Milvia Casato, Marcella Visentini, Gaafar Ragab, Patrice Cacoub
Summary: This study retrospectively analyzed patients with HCV-CryoVas treated with DAAs, finding that approximately 12.6% experienced vasculitis relapse after achieving sustained virologic response, predominantly showing skin involvement, renal involvement, and peripheral neuropathy. Relapses were mainly treated with glucocorticoids, with some patients requiring additional treatment modalities.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan
Summary: This retrospective study in incarcerated HCV-infected patients in Singapore showed that unrestricted access to DAA significantly increased treatment access, completion rate, and reduced treatment default rate, highlighting the impact of this strategy in HCV micro-elimination efforts.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Tsuyoshi Fukumoto, Tatsuya Minami, Makoto Moriyama, Tomoharu Yamada, Taijiro Wake, Mizuki Nishibatake Kinoshita, Naoto Fujiwara, Ryo Nakagomi, Takuma Nakatsuka, Masaya Sato, Kenichiro Enooku, Hayato Nakagawa, Mitsuhiro Fujishiro, Shuichiro Shiina, Kazuhiko Koike, Ryosuke Tateishi
Summary: This study aimed to evaluate the prognosis of hepatitis C-related hepatocellular carcinoma (C-HCC) in the era of direct-acting antivirals (DAAs). The results showed a significant improvement in the prognosis of C-HCC with the advent of DAAs, while the prognosis of nonviral HCC did not improve significantly.
HEPATOLOGY COMMUNICATIONS
(2022)